Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients Clinical research trials and A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients. A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients clinical trial. Human subjects often receive the most effective healthcare possible for their A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients

A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients



A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients

For Condition: HIV Infections
Status: Completed
Sponsor(s): Chiron Corporation ,
Synopsis: To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable subcutaneous regimen that will replicate the immunologic improvement demonstrated in the outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient population.
Details: Patients will receive subcutaneous Proleukin, and the MTD will be determined.
Eligibility:
Study Type:
  Interventional, Treatment, Dose Comparison, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Documented HIV infection by ELISA and Western blot. - CD4 count > 200 cells/mm3. Required: - FDA-approved antiretroviral therapy for at least 2 months prior to study entry.
Total Enrollment: 

Location and Contact Information:

Davies Med Ctr / c/o HIV Institute
San Francisco,  California,  94114
United States
 


Additional Information:
Study ID Numbers:
  085A;  CS-L293-09
Study Start Date: 
Record last reviewed: March 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002107

Other Hiv Infections Studies:
1. Safety and Tolerability of Z-100 in Patients with Early HIV Infection

2. Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

3. Treatment of Depression with Massage in HIV

4. Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

5. A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

Related Studies:

Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials

A Phase I Study of Subcutaneously Administered Proleukin (aldesleukin) in HIV-Infected Patients

Modify your Search

  Other HIV Infections Clinical Trials
  Other California Clinical Trials
  Other San Francisco Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103